We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Gets Complete Response Letter for Leqvio
Novartis has received a Complete Response Letter (CRL) from the FDA regarding a new drug application (NDA) for its cholesterol-lowering drug Leqvio (inclisiran).